Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
Opinion statement Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of resectable non-small cell lung cancer (NSCLC), overall survival (OS) in patients with resectable NSCLC remains poor. The incorporation of chemothera...
Gespeichert in:
| Veröffentlicht in: | Current treatment options in oncology 2021-10, Vol.22 (10), p.91-91, Article 91 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 10 |
| container_start_page | 91 |
| container_title | Current treatment options in oncology |
| container_volume | 22 |
| creator | Gutierrez-Sainz, Laura Cruz-Castellanos, Patricia Higuera, Oliver de Castro-Carpeño, Javier |
| description | Opinion statement
Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of resectable non-small cell lung cancer (NSCLC), overall survival (OS) in patients with resectable NSCLC remains poor. The incorporation of chemotherapy into the neoadjuvant setting has improved disease-free survival (DFS), time to distant recurrence, and OS. Furthermore, the incorporation of immunotherapy and the combination of chemotherapy and immunotherapy have improved pathological responses, which seems to be associated with increased survival. Therefore, immunotherapy represents a paradigm shift in treating resectable NSCLC. However, validation in large randomized trials is mandatory and a longer postoperative follow-up period is required. Additionally, neoadjuvant therapy trials offer an exceptional environment for testing predictive biomarkers. PD-L1 expression and tumor mutational burden (TMB) are the most helpful tools for predicting the likelihood of response with immunotherapy in metastatic NSCLC. However, in the neoadjuvant setting, PD-L1 expression and TMB have had opposite results until now. Recently, the immune profiling and some immune-related genes also appear to be involved in the prognosis and response to immunotherapy in NSCLC. Further prospective studies are needed to derive definitive conclusions. |
| doi_str_mv | 10.1007/s11864-021-00885-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2563717956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2563791242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-926ee1796143f062b3ad27ab7463ad012780c0df9834b525abeaffc12a9826a53</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMofqz-AQ9S8OIlmkzSpD1K8QsWFdFzSLtTt8s2XZNW8d-btX6ABy-ZgXnyzvAQcsjZKWdMnwXOMyUpA04Zy7KUqg2yy1MhqQKtN9c9aAoa8h2yF8KCMUgly7fJjpASpOR6lzzdYmdni-HVuj4p5th2TdsOruvn6O3qPWlccm_7Bl0fkremnycPGLDqbbnE5LZzNLR2uUwKjM90cM9JYV2Ffp9s1XYZ8OCrTsjT5cVjcU2nd1c3xfmUVkKnPc1BIXKdKy5FzRSUws5A21JLFTvGQWesYrM6z4QsU0htibauKw42z0DZVEzIyZi78t3LgKE3bROqeIx12A3BQKqEjgtimZDjP-iiG7yL141UzkFCpGCkKt-F4LE2K9-01r8bzsxauhmlmyjdfEo36-ijr-ihbHH28-XbcgTECIQ4cs_of3f_E_sBGyqL0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563791242</pqid></control><display><type>article</type><title>Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gutierrez-Sainz, Laura ; Cruz-Castellanos, Patricia ; Higuera, Oliver ; de Castro-Carpeño, Javier</creator><creatorcontrib>Gutierrez-Sainz, Laura ; Cruz-Castellanos, Patricia ; Higuera, Oliver ; de Castro-Carpeño, Javier</creatorcontrib><description>Opinion statement
Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of resectable non-small cell lung cancer (NSCLC), overall survival (OS) in patients with resectable NSCLC remains poor. The incorporation of chemotherapy into the neoadjuvant setting has improved disease-free survival (DFS), time to distant recurrence, and OS. Furthermore, the incorporation of immunotherapy and the combination of chemotherapy and immunotherapy have improved pathological responses, which seems to be associated with increased survival. Therefore, immunotherapy represents a paradigm shift in treating resectable NSCLC. However, validation in large randomized trials is mandatory and a longer postoperative follow-up period is required. Additionally, neoadjuvant therapy trials offer an exceptional environment for testing predictive biomarkers. PD-L1 expression and tumor mutational burden (TMB) are the most helpful tools for predicting the likelihood of response with immunotherapy in metastatic NSCLC. However, in the neoadjuvant setting, PD-L1 expression and TMB have had opposite results until now. Recently, the immune profiling and some immune-related genes also appear to be involved in the prognosis and response to immunotherapy in NSCLC. Further prospective studies are needed to derive definitive conclusions.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-021-00885-6</identifier><identifier>PMID: 34424417</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B7-H1 Antigen - genetics ; Biomarkers, Tumor - genetics ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - surgery ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical trials ; Humans ; Immune Checkpoint Inhibitors - administration & dosage ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy ; Ipilimumab - administration & dosage ; Lung cancer ; Lung Cancer (TA Leal ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - surgery ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Morbidity ; Mutation ; Neoadjuvant Therapy ; Nivolumab - administration & dosage ; Non-small cell lung carcinoma ; Oncology ; Patients ; PD-L1 protein ; Section Editor ; Small cell lung carcinoma ; Topical Collection on Lung Cancer</subject><ispartof>Current treatment options in oncology, 2021-10, Vol.22 (10), p.91-91, Article 91</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-926ee1796143f062b3ad27ab7463ad012780c0df9834b525abeaffc12a9826a53</citedby><cites>FETCH-LOGICAL-c375t-926ee1796143f062b3ad27ab7463ad012780c0df9834b525abeaffc12a9826a53</cites><orcidid>0000-0001-7356-5043</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-021-00885-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-021-00885-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34424417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gutierrez-Sainz, Laura</creatorcontrib><creatorcontrib>Cruz-Castellanos, Patricia</creatorcontrib><creatorcontrib>Higuera, Oliver</creatorcontrib><creatorcontrib>de Castro-Carpeño, Javier</creatorcontrib><title>Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement
Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of resectable non-small cell lung cancer (NSCLC), overall survival (OS) in patients with resectable NSCLC remains poor. The incorporation of chemotherapy into the neoadjuvant setting has improved disease-free survival (DFS), time to distant recurrence, and OS. Furthermore, the incorporation of immunotherapy and the combination of chemotherapy and immunotherapy have improved pathological responses, which seems to be associated with increased survival. Therefore, immunotherapy represents a paradigm shift in treating resectable NSCLC. However, validation in large randomized trials is mandatory and a longer postoperative follow-up period is required. Additionally, neoadjuvant therapy trials offer an exceptional environment for testing predictive biomarkers. PD-L1 expression and tumor mutational burden (TMB) are the most helpful tools for predicting the likelihood of response with immunotherapy in metastatic NSCLC. However, in the neoadjuvant setting, PD-L1 expression and TMB have had opposite results until now. Recently, the immune profiling and some immune-related genes also appear to be involved in the prognosis and response to immunotherapy in NSCLC. Further prospective studies are needed to derive definitive conclusions.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B7-H1 Antigen - genetics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical trials</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - administration & dosage</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Ipilimumab - administration & dosage</subject><subject>Lung cancer</subject><subject>Lung Cancer (TA Leal</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - surgery</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Morbidity</subject><subject>Mutation</subject><subject>Neoadjuvant Therapy</subject><subject>Nivolumab - administration & dosage</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>Section Editor</subject><subject>Small cell lung carcinoma</subject><subject>Topical Collection on Lung Cancer</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMofqz-AQ9S8OIlmkzSpD1K8QsWFdFzSLtTt8s2XZNW8d-btX6ABy-ZgXnyzvAQcsjZKWdMnwXOMyUpA04Zy7KUqg2yy1MhqQKtN9c9aAoa8h2yF8KCMUgly7fJjpASpOR6lzzdYmdni-HVuj4p5th2TdsOruvn6O3qPWlccm_7Bl0fkremnycPGLDqbbnE5LZzNLR2uUwKjM90cM9JYV2Ffp9s1XYZ8OCrTsjT5cVjcU2nd1c3xfmUVkKnPc1BIXKdKy5FzRSUws5A21JLFTvGQWesYrM6z4QsU0htibauKw42z0DZVEzIyZi78t3LgKE3bROqeIx12A3BQKqEjgtimZDjP-iiG7yL141UzkFCpGCkKt-F4LE2K9-01r8bzsxauhmlmyjdfEo36-ijr-ihbHH28-XbcgTECIQ4cs_of3f_E_sBGyqL0w</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Gutierrez-Sainz, Laura</creator><creator>Cruz-Castellanos, Patricia</creator><creator>Higuera, Oliver</creator><creator>de Castro-Carpeño, Javier</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7356-5043</orcidid></search><sort><creationdate>20211001</creationdate><title>Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer</title><author>Gutierrez-Sainz, Laura ; Cruz-Castellanos, Patricia ; Higuera, Oliver ; de Castro-Carpeño, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-926ee1796143f062b3ad27ab7463ad012780c0df9834b525abeaffc12a9826a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B7-H1 Antigen - genetics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical trials</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - administration & dosage</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Ipilimumab - administration & dosage</topic><topic>Lung cancer</topic><topic>Lung Cancer (TA Leal</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - surgery</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Morbidity</topic><topic>Mutation</topic><topic>Neoadjuvant Therapy</topic><topic>Nivolumab - administration & dosage</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>Section Editor</topic><topic>Small cell lung carcinoma</topic><topic>Topical Collection on Lung Cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gutierrez-Sainz, Laura</creatorcontrib><creatorcontrib>Cruz-Castellanos, Patricia</creatorcontrib><creatorcontrib>Higuera, Oliver</creatorcontrib><creatorcontrib>de Castro-Carpeño, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gutierrez-Sainz, Laura</au><au>Cruz-Castellanos, Patricia</au><au>Higuera, Oliver</au><au>de Castro-Carpeño, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>22</volume><issue>10</issue><spage>91</spage><epage>91</epage><pages>91-91</pages><artnum>91</artnum><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement
Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of resectable non-small cell lung cancer (NSCLC), overall survival (OS) in patients with resectable NSCLC remains poor. The incorporation of chemotherapy into the neoadjuvant setting has improved disease-free survival (DFS), time to distant recurrence, and OS. Furthermore, the incorporation of immunotherapy and the combination of chemotherapy and immunotherapy have improved pathological responses, which seems to be associated with increased survival. Therefore, immunotherapy represents a paradigm shift in treating resectable NSCLC. However, validation in large randomized trials is mandatory and a longer postoperative follow-up period is required. Additionally, neoadjuvant therapy trials offer an exceptional environment for testing predictive biomarkers. PD-L1 expression and tumor mutational burden (TMB) are the most helpful tools for predicting the likelihood of response with immunotherapy in metastatic NSCLC. However, in the neoadjuvant setting, PD-L1 expression and TMB have had opposite results until now. Recently, the immune profiling and some immune-related genes also appear to be involved in the prognosis and response to immunotherapy in NSCLC. Further prospective studies are needed to derive definitive conclusions.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34424417</pmid><doi>10.1007/s11864-021-00885-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7356-5043</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-2729 |
| ispartof | Current treatment options in oncology, 2021-10, Vol.22 (10), p.91-91, Article 91 |
| issn | 1527-2729 1534-6277 1534-5277 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2563717956 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - genetics Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Chemotherapy, Adjuvant Clinical trials Humans Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Ipilimumab - administration & dosage Lung cancer Lung Cancer (TA Leal Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - surgery Medical prognosis Medicine Medicine & Public Health Metastases Morbidity Mutation Neoadjuvant Therapy Nivolumab - administration & dosage Non-small cell lung carcinoma Oncology Patients PD-L1 protein Section Editor Small cell lung carcinoma Topical Collection on Lung Cancer |
| title | Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A30%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20Chemoimmunotherapy%20in%20Patients%20with%20Resectable%20Non-small%20Cell%20Lung%20Cancer&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Gutierrez-Sainz,%20Laura&rft.date=2021-10-01&rft.volume=22&rft.issue=10&rft.spage=91&rft.epage=91&rft.pages=91-91&rft.artnum=91&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-021-00885-6&rft_dat=%3Cproquest_cross%3E2563791242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563791242&rft_id=info:pmid/34424417&rfr_iscdi=true |